Also known as Symlin · AC-137 · Tripro-amylin · Amylin analog
The stabilized amylin analog — three prolines that stop native amylin from aggregating, turning the beta cell’s second satiety hormone into an injectable diabetes drug.
Research refreshed
Pramlintide (Symlin) is a synthetic analog of amylin, the hormone co-secreted with insulin from the pancreatic beta cell. Native human amylin is too aggregation-prone to formulate, so pramlintide substitutes proline at positions 25, 28 and 29 — swaps that block the β-sheet stacking without losing receptor activity. The result is the first approved amylin-receptor agonist: a mealtime add-on to insulin in type 1 and type 2 diabetes that slows gastric emptying, suppresses glucagon, and curbs appetite.
Amylin is insulin’s co-secreted partner, but native human amylin cannot be bottled: it misfolds into the islet amyloid found in type 2 diabetes, aggregating on the resin and in solution. Pramlintide is the engineering answer — three proline substitutions (Ala25, Ser28, Ser29 → Pro) that break the amyloid-forming β-sheet while preserving amylin’s biology, giving a soluble, shelf-stable analog.
Approved in 2005 as Symlin, pramlintide is given before meals alongside insulin in type 1 and type 2 diabetes, where it blunts post-meal glucose spikes and modestly aids weight control — the parts of glucose regulation insulin alone handles poorly.
Pramlintide is the proof of concept for the whole amylin class. Its short duration made it a three-times-daily injection, which limited uptake, but it validated the amylin receptor as a satiety target — the opening that longer-acting analogs such as cagrilintide (profiled separately) now exploit at the front of obesity drug development.
Amylin-receptor agonism (a calcitonin-receptor core complexed with RAMP subunits). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally to reduce food intake — complementing, not duplicating, injected insulin.
Behind every vial of Pramlintide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Pramlintide, specifically, is brought into being.
On paper, Pramlintide is C171H267N51O53S2 — about 3,949.4 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Pramlintide's chain is short but unusual — it carries non-natural residues that help it resist enzymatic breakdown, but demand specialized, costlier building blocks and careful coupling on the synthesizer. It also carries a disulfide bridge, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Pramlintide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Pramlintide proves itself: identity confirmed by mass spectrometry against its ~3,949.4 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Pramlintide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Pramlintide is amylin re-engineered for manufacturability: the 2–7-disulfide, C-terminally amidated 37-mer with Ala25/Ser28/Ser29 → Pro. The three prolines deliberately break the β-sheet stacking that makes native amylin aggregate on the resin, so pramlintide is markedly easier to make and purify than amylin itself, though the disulfide and C-terminal amide still set the quality bar.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Pramlintide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Pramlintide (Symlin) is a synthetic amylin analog with three proline substitutions that prevent the aggregation of native human amylin, making it stable enough to inject as a mealtime add-on to insulin.
It is human amylin with Ala25, Ser28 and Ser29 each replaced by proline — changes that block amyloid formation while keeping amylin-receptor activity.
Both are amylin-receptor agonists. Pramlintide is the short-acting, approved diabetes drug; cagrilintide is a long-acting analog developed for obesity, often paired with a GLP-1 agonist.
No — this is a research and educational reference, not dosing guidance.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.